Neurofilament Light Chain in Serum of Cancer Patients with Acute Neurological Complications

Overview

Journal CNS Oncol

Specialty Oncology

Date 2024 Aug 13

PMID 39136375

Authors

Amulya Gottiparthy

Keng Lam

Suprateek Kundu

Zixi Yang

Ivo Tremont-Lukats

Sudhakar Tummala

Affiliations

Soon will be listed here.

Abstract

Neurofilament light chain (NfL) is a nonspecific sensitive biomarker of axonal damage. This case series identified cancer patients with neurological complications who had serum NfL measurements and paired these results to outcomes. NfL serum levels were available in 15 patients with hematological malignancies or solid tumors. The neurological complications studied were immune effector cell-associated neurotoxicity syndrome, immune checkpoint inhibitor-related encephalopathy, anoxic brain injury, Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis, transverse myelitis, paraneoplastic syndrome, central nervous system demyelinating disorder and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. All patients but one with serum NfL >900 pg/ml died during hospitalization. Serum NfL levels consistently corresponded to death, disease severity or recovery in this series.

References

Huehnchen P, Schinke C, Bangemann N, Dordevic A, Kern J, Maierhof S . Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight. 2022; 7(6). PMC: 8986065. DOI: 10.1172/jci.insight.154395. View

Barro C, Chitnis T, Weiner H . Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol. 2020; 7(12):2508-2523. PMC: 7732243. DOI: 10.1002/acn3.51234. View

Argyriou A, Karteri S, Bruna J, Mariotto S, Simo M, Velissaris D . Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. Support Care Cancer. 2021; 30(2):1807-1814. DOI: 10.1007/s00520-021-06509-x. View

Kim S, Kim K, Hyun J, Kim J, Seo S, Kim H . Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel-induced peripheral neuropathy in patients with gynecological cancers. Front Oncol. 2022; 12:942960. PMC: 9428708. DOI: 10.3389/fonc.2022.942960. View

Simren J, Andreasson U, Gobom J, Calvet M, Borroni B, Gillberg C . Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years. Brain Commun. 2022; 4(4):fcac174. PMC: 9297091. DOI: 10.1093/braincomms/fcac174. View

Piepgras J, Muller A, Steffen F, Lotz J, Loquai C, Zipp F . Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy. Eur J Neurol. 2021; 28(3):1086-1089. DOI: 10.1111/ene.14692. View

Guasp M, Martin-Aguilar L, Sabater L, Bioque M, Armangue T, Martinez-Hernandez E . Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. Neurology. 2022; 98(14):e1489-e1498. DOI: 10.1212/WNL.0000000000200021. View

Zhao Y, Xin Y, Meng S, He Z, Hu W . Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis. Neurosci Biobehav Rev. 2019; 102:123-138. DOI: 10.1016/j.neubiorev.2019.04.014. View

Falzone Y, Russo T, Domi T, Pozzi L, Quattrini A, Filippi M . Current application of neurofilaments in amyotrophic lateral sclerosis and future perspectives. Neural Regen Res. 2021; 16(10):1985-1991. PMC: 8343335. DOI: 10.4103/1673-5374.308072. View

10.

Ashton N, Janelidze S, Al Khleifat A, Leuzy A, van der Ende E, Karikari T . A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021; 12(1):3400. PMC: 8185001. DOI: 10.1038/s41467-021-23620-z. View

11.

Bazarian J . Neuron-specific enolase correlates with other prognostic markers after cardiac arrest. Neurology. 2011; 77(20):1856. DOI: 10.1212/WNL.0b013e31823c1141. View

12.

Stammet P, Collignon O, Hassager C, Wise M, Hovdenes J, Aneman A . Neuron-Specific Enolase as a Predictor of Death or Poor Neurological Outcome After Out-of-Hospital Cardiac Arrest and Targeted Temperature Management at 33°C and 36°C. J Am Coll Cardiol. 2015; 65(19):2104-14. DOI: 10.1016/j.jacc.2015.03.538. View

13.

Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H . Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019; 90(8):870-881. DOI: 10.1136/jnnp-2018-320106. View

14.

Mortensen C, Steffensen K, Simonsen E, Herskind K, Madsen J, Olsen D . Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel-induced peripheral neuropathy in patients with ovarian cancer. Pain. 2022; 164(7):1502-1511. DOI: 10.1097/j.pain.0000000000002840. View

15.

Winther-Larsen A, Hviid C, Meldgaard P, Sorensen B, Sandfeld-Paulsen B . Neurofilament Light Chain as A Biomarker for Brain Metastases. Cancers (Basel). 2020; 12(10). PMC: 7600301. DOI: 10.3390/cancers12102852. View